Senior Vice President, Product Strategy and Market Development
Bill Hatfield, Senior Vice President of Product Strategy and Market Development at Karyopharm Therapeutics is responsible for the strategic planning and medical affairs activities to prepare for the launch of selinexor as a novel therapy for patients across a broad range of cancers.
He is also responsible for Karyopharm’s patient advocacy activities and the development of the commercial organization and launch plan.
Bill has over thirty-five years of industry experience with Bristol Myers Squibb, Millennium Pharmaceuticals, Genzyme, Sanofi, and Karyopharm including the past 22 years in the support of the development and launch of cancer therapies.
He lead the development of commercial teams for Velcade in multiple myeloma, Campath for CLL, Clofarabine for Pediatric ALL and adult AML, Fedratinib for myelofibrosis as well as other many other compounds in clinical development for a broad range of solid tumors and hematologic malignancies.
Bill has a marketing degree from the Boston University School of Management
Senior Vice President, Regulatory Affairs, Quality, and Pharmacovigilance